Danaher Corporation (NYSE:DHR) Shares Acquired by Kavar Capital Partners Group LLC

Kavar Capital Partners Group LLC boosted its holdings in shares of Danaher Corporation (NYSE:DHR) by 2.4% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,757 shares of the conglomerate’s stock after purchasing an additional 1,100 shares during the quarter. Danaher makes up approximately 1.6% of Kavar Capital Partners Group LLC’s holdings, making the stock its 16th largest holding. Kavar Capital Partners Group LLC’s holdings in Danaher were worth $9,790,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in DHR. Vanguard Group Inc. increased its stake in shares of Danaher by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 59,750,122 shares of the conglomerate’s stock worth $13,715,641,000 after buying an additional 315,912 shares during the last quarter. Geode Capital Management LLC grew its holdings in Danaher by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate’s stock worth $3,056,996,000 after acquiring an additional 315,446 shares in the last quarter. Norges Bank bought a new stake in shares of Danaher in the 4th quarter worth about $2,130,740,000. Northern Trust Corp raised its stake in shares of Danaher by 14.3% in the 4th quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate’s stock valued at $1,821,477,000 after purchasing an additional 992,594 shares in the last quarter. Finally, Capital World Investors lifted its position in shares of Danaher by 32.7% during the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate’s stock worth $1,460,215,000 after purchasing an additional 1,566,658 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Up 1.7%

Shares of Danaher stock opened at $200.85 on Thursday. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $281.70. The company has a market capitalization of $143.74 billion, a P/E ratio of 39.00, a PEG ratio of 2.77 and a beta of 0.77. The business’s fifty day moving average price is $194.31 and its two-hundred day moving average price is $209.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.26. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. As a group, research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.64%. Danaher’s dividend payout ratio (DPR) is presently 24.85%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on DHR. Evercore ISI lowered their price objective on Danaher from $240.00 to $230.00 and set an “outperform” rating for the company in a report on Tuesday, April 22nd. Bank of America dropped their price target on Danaher from $265.00 to $230.00 in a research report on Monday, April 14th. Jefferies Financial Group reduced their price objective on Danaher from $260.00 to $230.00 and set a “buy” rating on the stock in a research note on Tuesday, April 22nd. Wall Street Zen lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Monday, June 9th. Finally, The Goldman Sachs Group reduced their price target on shares of Danaher from $260.00 to $240.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 23rd. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $248.61.

Insider Activity at Danaher

In related news, EVP Christopher Paul Riley sold 15,805 shares of the firm’s stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the transaction, the executive vice president now owns 15,179 shares of the company’s stock, valued at $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business’s stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the sale, the chairman now owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.